It's worth noting in the companies RI document -
iii. Expand external collaboration alliances to generate additional preclinical data and intellectual property with a focus on haematological malignancies.
iv. Fund activities related to potential partnering/out-licensing of PAT-SM6.
Onyx are already recruiting and have also previously carried out early stage clinical trials aimed at Hematologic Malignancies. Patrys are obviously working to build value towards suitors against any future move on SM6
onyx, page-11
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1853666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable